Hydroxyethylene-based β-secretase inhibitors and use...

Details Hydroxyethylene-based β-secretase inhibitors and use... Hydroxyethylene-based β-secretase inhibitors and use...

2005-09-19

2010-02-09

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S365000, C548S204000, C546S269700

Reexamination Certificate

active

07659289

ABSTRACT:
The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

REFERENCES:
patent: 4801575 (1989-01-01), Pardridge
patent: 4861760 (1989-08-01), Mazuel et al.
patent: 4911920 (1990-03-01), Jani et al.
patent: 5212162 (1993-05-01), Missel et al.
patent: 5403841 (1995-04-01), Lang et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6287792 (2001-09-01), Pardridge et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6372250 (2002-04-01), Pardridge
patent: 7335632 (2008-02-01), Ghosh et al.
patent: 2003/0215398 (2003-11-01), Frey, II
patent: 2003/0215432 (2003-11-01), Matalon
patent: 2003/0216589 (2003-11-01), Gschneidner et al.
patent: 2004/0101904 (2004-05-01), Pardridge et al.
patent: 2004/0102369 (2004-05-01), Wu et al.
patent: 2004/0110928 (2004-06-01), Crisanti et al.
patent: 2004/0121947 (2004-06-01), Ghosh et al.
patent: WO-89/10134 (1989-11-01), None
patent: WO-96/05309 (1996-02-01), None
patent: WO-96/05309 (1996-02-01), None
patent: WO-03/039454 (2003-05-01), None
patent: WO-03/039454 (2003-05-01), None
patent: WO-2006/034296 (2006-03-01), None
patent: WO-2006/034296 (2006-03-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205-213.
Ghosh et al. (J Med Chem. Aug. 30, 2001;44(18):2865-8).
Vippagunta et al, “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?”, Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Banker et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banner, D. et al. (1993). “Serine Proteases: 3D Structures, Mechanisms of Action and Inhibitors,” Chapter 3 inPerspectives in Medicinal Chemistry, Testa, B. et al. eds., Verlag Helvetica Chimica Acta: Basel, Switzerland, pp. 27-43.
Abbott, N.J. et al. (Mar. 1996). “Transporting Therapeutics Across the Blood-Brain Barrier,”Mol. Med. Today2(3):106-113.
Banks, W.A. et al. (Nov./Dec. 1992). “Permeability of the Blood-Brain Barrier to Peptides: An Approach to the Development of Therapeutically Useful Analogs,”Peptides13(6):1289-1294.
Begley, D.J. (Feb. 1996). “The Blood-Brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System,”J. Pharm. Pharmacol. 48(2):136-146.
Bertling, W.M. et al. (Jun. 1991). “Use of Liposomes, Viral Capsids, and Nanoparticles as DNA Carriers,”Biotechnol. Appl. Biochem. 13(3):390-405.
Bickel, U. et al. (Mar. 1, 2001). “Delivery of Peptides and Proteins Through the Blood-Brain Barrier,”Adv. Drug Deliv. Rev. 46(I-3):247-279.
Bieth, J. (1974). “Some Kinetic Consequences of the Tight Binding of Protein-Proteinase-Inhibitors to Proteolytic Enzymes and Their Application to the Determination of Dissociation Constants,” Bayer-Symposium V “Proteinase Inhibitors”,Proceedings of the 2nd International Research Conference on Proteinase Inhibitors, Grosse Ledder, Fed. Rep. Germany, Oct. 16-20, 1973, pp. 463-469.
Black, K.L. et al. (Nov. 1994). “Enzymatic Barrier Protects Brain Capillaries From Leukotriene C4,”J. Neurosurg.81(5):745-751.
Bobo, R.H. et al. (Mar. 15, 1994). “Convection-Enhanced Delivery of Macromolecules in the Brain,”Proc. Natl. Acad. Sci. USA91(6):2076-2080.
Bodor, N. et al. (Dec. 18, 1981). “Site-Specific, Sustained Release of Drugs to the Brain,”Science214(4527):1370-1372.
Bodor, N. et al. (1995). “Molecular Packaging,” Chapter 14 inPeptide-Based Drug Design: Controlling Transport and Metabolism, Taylor, M.D. et al. eds., American Chemical Society: Washington, DC, pp. 317-337.
Bodor, N. et al. (Oct.-Dec. 1997). “Drug Targeting via Retrometabolic Approaches,”Pharmacol. Ther. 76(1-3):1-27.
Brem, H. et al. (Jul./Aug. 1996). “Polymer-Based Drug Delivery to the Brain,”Sci. Med. 3(4):52-61.
Calvo, P. et al. (Aug. 2001). “Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery,”Pharm. Res. 18(8):1157-1166.
Chavany, C. et al. (Apr. 1992). “Polyalkylcyanoacrylate Nanoparticles as Polymeric Carriers for Antisense Oligonucleotides,”Pharm. Res. 9(4):441-449.
Chavany, C. et al. (Sep. 1994). “Adsorption of Oligonucleotides Onto Polyisohexylcyanoacrylate Nanoparticles Protects Them Against Nucleases and Increases Their Cellular Uptake,”Pharm. Res. 11(9):1370-1378.
Chen, P. et al. (Sep. 24, 1998). “Strategies to Target Kyotorphin Analogues to the Brain,”J. Med. Chem. 41 (20):3773-3781.
Coloma, M.J. et al. (Mar. 2000). “Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor,”Pharm. Res. 17(3):266-274.
De Strooper, B. et al. (Jan. 22, 1998). “Deficiency of Presenilin-1 Inhibits the Normal Cleavage of Amyloid Precursor Protein,”Nature391:387-390.
Doran, S.E. et al. (May 1995). “Gene Expression From Recombinant Viral Vectors in the Central Nervous System After Blood-Brain Barrier Disruption,”Neurosurg. 36(5):965-970.
Emerich, D.F. et al. (2001). “The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier: From Concept to Clinical Evaluation,”Clin. Pharmacokinet. 40(2):105-123.
Ermolieff, J. et al. (Oct. 10, 2000). “Proteolytic Activation of Recombinant Pro-memapsin 2 (Pro-β-secretase) Studied With New Fluorogenic Substrates,”Biochemistry39(40):12450-12456.
Fray, A.H. et al. (1986). “A Short, Stereoselective Synthesis of the Lactone Precursor to2R, 4S, 5SHydroxyethylene Dipeptide Isoteres,” J. Org. Chem. 51(25):4828-4833.
Golden, P.L. et al. (Jan. 1997). “Human Blood-Brain Barrier Leptin Receptor. Binding and Endocytosis in Isolated Human Brain Microvessels,”J. Clin. Invest. 99(1):14-18.
Han, H.-K. et al. (2000). “Targeted Prodrug Design to Optimize Drug Delivery,”AAPS PharmSci2(1):1-11.
Harbaugh, R.E. et al. (Dec. 1988). “Use of Implantable Pumps for Central Nervous System Drug Infusions to Treat Neurological Disease,”Neurosurg. 23(6):693-698.
Hom, R.K. et al. (2004). “Design and Synthesis of Hyrdoxyethylene-Based Peptidomimetic Inhibitors of Human β-Secretase,”J. Med. Chem. 47(1):158-164.
Hsiao, K. et al. (Oct. 4, 1996). “Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice,”Science274:99-102.
Huang, T.-Y. et al. (1999). “ACNU, MTX and 5-FU Penetration of Rat Brain Tissue and Tumors,”J. Neurooncol. 45(1):9-17.
Hussain, I. et al. (Jun. 29, 2001). “Prodomain Processing of Asp1 (BACE2) Is Autocatalytic,”J. Biol. Chem. 276(26):23322-23328.
Huwyler, J. et al. (Nov. 26, 1996). “Brain Drug Delivery of Small Molecules Using Immunoliposomes,”Proc. Natl. Acad. Sci. USA93(24):14164-14169.
Huwyler, J. et al. (Sep. 1997). “Receptor Mediated Delivery of Daunomycin Using Immunoliposomes: Pharmacokinetics and Tissue Distribution in the Rat,”J. Pharmcol. Exp. Ther. 282(3):1541-1546.
Illum, L. (Dec. 2002). “Nasal Drug Delivery: New Developments and Strategies,”Drug Discov. Today7(23):1184-1189.
International Search Report mailed Jul. 19, 2006 for PCT Application No. PCT/US2005/033709 filed Sep. 19, 2005, 5 pages.
Kreil, G. et al. (Sep. 1995). “Hyaluronidases—a Group of Neglected Enzymes,”Protein Sci. 4(9):1666-1669.
Kreuter, J. (Mar. 23, 2001). “Nanoparticulate Systems for Brain Delivery of Drugs,”Adv. Drug Deliv. Rev. 47(1):65-81.
Kreuter, J. (2002). “Transport of Drugs Across the Blood-Brain Barrier by Nanoparticles,”Curr. Med. Chem. 2(3):241-249.
Kreuter, J. et al. (Mar.

Affiliated with

Also associated with

Rating

Hydroxyethylene-based β-secretase inhibitors and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxyethylene-based β-secretase inhibitors and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyethylene-based β-secretase inhibitors and use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4198919